Two of the most widely used medicinal plants in South Asian traditional medicine may be stronger together than apart when it ...
Lead candidate Nu-3 is a topically formulated Bisphosphocin®, designed to rapidly kill microbes while reducing the risk ...
Zacks Small Cap Research on MSN
LABT: First patient dosed in phase 2a trial of Nu-3 for infected diabetic foot ulcers
By David Bautz, PhD NASDAQ: LABT READ THE FULL LABT RESEARCH REPORT Business Update First Patient Dosed in Phase 2a Trial of ...
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) reported positive preclinical antimicrobial data for Nu-3 against recent clinical isolates from infected diabetic foot ulcers, ahead of Phase 2a topline ...
Lakewood-Amedex Biotherapeutics Inc. announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3. Nu-3 is currently being ...
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results